Neurogen Corp.

Steve assumed the role of Chief Executive Officer of Neurogen on February 5, 2008. He had previously served in various roles including Executive Vice-President and Chief Operating Officer. Steve has played key roles in the operations of Neurogen since joining the Company in 1994. He established drug discovery and development partnerships for Neurogen valued at over $400 million and has also guided the Company in raising over $200 million in equity financings, as well as providing critical business and marketing perspectives to scientific decisions. Prior to becoming CEO, Steve had been responsible for the business operations of Neurogen, including the business development, finance, and legal functions of the Company. Prior to joining Neurogen as Chief Financial Officer in 1994, he practiced as a corporate and securities attorney with Milbank, Tweed, Hadley and McCloy. At Milbank, Steve focused on transactions which raised capital in public and private markets for established companies, as well as the formation of numerous joint ventures and alliances. He began his career with Arthur Andersen & Co., where he focused on auditing and advising clients in regulated industries. Steve holds a B.S. in accounting from Southern Nazarene University and a J.D. from Vanderbilt University.

Tom is responsible for identifying and securing business opportunities for Neurogen, including collaborative partnerships and the acquisition of technology and assets. He is also responsible for alliance management for the Company...

Al started with Neurogen in 1989, and has been the cornerstone of our medicinal chemistry and informatics initiatives, where he was instrumental in developing our Accelerated Intelligent Drug Discovery (AIDD ) technology. Al has helped Neurogen become a world leader in developing compounds for challenging drug targets. Al is responsible for Neurogen's drug discovery operations, including our chemistry, biology, and discovery technologies organizations. Prior to joining Neurogen, Al was Manager of Neuroscience Chemistry and a Distinguished Research Fellow at Ciba-Geigy. Previously he had served as a research scientist at Pfizer Inc, where he worked on anti-diabetic agents. Al holds a B.S. degree in chemistry from Stevens Institute of Technology in New Jersey and was awarded his Ph.D. in chemistry from Harvard University in Massachusetts.

Jim's research has focused on investigating the structure and function of G-protein coupled receptors and ion channels that are predominantly expressed in the nervous and endocrine systems of the body. These studies have encompassed: receptor molecular cloning, functional expression, structure-activity relationships evaluations, physiological functions and the regulation of gene expression in the central nervous system. Prior to joining Neurogen he held a succession of positions of increasing responsibility at the Washington University School of Medicine in St. Louis, Missouri. He was a tenured faculty member in the Department of Anatomy and Neurobiology, and most recently was Professor of Neurobiology and Co-Director of the Washington University Medical Scientist Training Program. Jim holds a B.S. degree in biology and a Ph.D in physiological chemistry from the University of Wisconsin.

Charles is responsible for research informatics and information technologies, biophysical properties research, and computational chemistry. Joining Neurogen in 1993, he's played a prominent role in the development and implementation of our Accelerated Intelligent Drug Discovery (AIDD ) technology, which integrates high speed compound synthesis, high throughput screening and advanced informatics. Charles is the architect of the informatics system used in the AIDD program and is responsible for the integration of computational chemistry and informatics with automation and control of the chemical synthesis and screening robotics. AIDD can generate drug discovery data in as little as a two-week period, which compares to a several month-long cycle in other drug discovery programs at both large and small pharma companies. His research interests include the development of automated and assisted methodologies for pharmacophore recognition and model development, as well as molecular level interactions key to drug receptor molecular recognition and the conveyance of drug-like properties. Prior to joining Neurogen, Charles held positions of increasing responsibility in chemistry at Eli Lilly and Dow Elanco. Charles holds a B.S. degree in chemistry from the University of North Carolina, Greensboro, and a Ph.D in chemistry from Harvard University in Massachusetts.

George is responsible for the full range of functions required to advance compounds from the preclinical development stage into Phase 1 clinical studies, or to human testing, including pharmaceutical sciences, process chemistry, and preclinical safety. He joined the medicinal chemistry group at Neurogen in 1997 as Senior Research Fellow and assumed several positions of increasing responsibility at the Company, being promoted to Executive Director, Early Development in 2006 and then to Vice-President in 2007. Prior to joining Neurogen, George had served on the scientific staff of Hoechst Marion Roussel Inc., Cincinnati Research Institute, now part of Sanofi-Aventis, where he was a discovery chemist project team leader. Prior to obtaining his Ph.D., he worked as a chemist at E.I. Du Pont de Nemours & Co., Experimental Station. George holds a B.S. degree in chemistry, summa cum laude, from Marietta College, Marietta, Ohio and a Ph.D. in organic chemistry from The Ohio State University, Columbus, Ohio.

Ken has been responsible for all clinical development activities for our most advanced compound, adipiplon, for the treatment of insomnia--eight clinical studies in over 600 subjects, including two successful Phase 2b studies announced in June 2007. He has also been a key contributor to building the Company's clinical development infrastructure, which has been critical to Neurogen's transition from an early-stage discovery company to a mid-stage drug development firm. Ken joined Neurogen in January 2005 as Senior Director, Clinical Development and Operations and was promoted to Executive Director the following year. Before joining Neurogen, he had served as Global Clinical Leader for new chemical entities at Bayer Pharmaceuticals in West Haven, Connecticut, where he headed clinical development for vardenafil (Levitra ) and was also closely involved with registration, launch, and marketing planning. Vardenafil was approved by the FDA in 2003. Previously Ken was Medical Director for Bayer in South Africa, where he was responsible for the Company's Pharmaceutical Medical Department and Bayer's medical affairs in African countries. Prior to his experience at Bayer, he practiced as a pediatrician and pediatric cardiologist at hospitals in Durban and Cape Town. Ken holds a B.Sc. in medicine and his M.B.B.Ch. from the University of the Witwatersrand in Johannesburg. He also holds a doctorate in immunology from the University of Cape Town.

Ricardo is responsible for leading Neurogen's Toxicology Department, ensuring that each of the Company's drug programs is supported with the technical and strategic expertise to execute appropriate GLP and non-GLP toxicology st...

Dr. Felix J. Baker has served as a director of Neurogen Corporation since May 1999. Dr. Baker is a Managing Member of Baker Bros. Advisors, LLC, which he and his brother, Julian Baker, founded in 2000. Dr. Baker's firm manages Baker Brothers Investments, a family of long-term investment funds for major university endowments and foundations, which are focused on publicly traded life sciences companies. Dr. Baker's career as a fund-manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch Family. Dr. Baker holds a B.S. and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school. He is also a director of Conjuchem Inc., Seattle Genetics, Inc., and Trimeris, Inc.

James Gregory is Chief Software Architect of Core Informatics, bringing over 16 years of experience in software engineering, system design, project management and science to Core Informatics. He has significant experience in both academic and pharmaceutical research settings. Jim has led a wide range of informatics projects including the development of systems for: Automated High Throughput Screening, High Speed Chemical Synthesis with QC/QA, PK and In-Vivo Study Management, Archive Reformatting as well as Data exchange & integration systems to collaborate with corporate partners. As head of the Research Informatics department at Neurogen Corporation, Jim lead a team of software engineers that developed a fully integrated drug discovery platform that encompassed all phases of the small molecule drug discovery process from synthesis, QA/QC, High Throughput Screening, secondary screening, Drug Metabolism and PK to in-vivo efficacy studies. This system was a key component of Neurogen's AIDDO (Accelerated Intelligent Drug Discovery) platform that was licensed to Pfizer for $29M and has helped Neurogen raise over $250M and identify more than 10 drug candidates that entered clinical trials. Jim's work experience includes Yale University and Neurogen Corporation where he worked with increasing levels of responsibility from biologist to Chief LIMS Architect. Jim holds undergraduate and graduate degrees in biology and computer science from Southern Connecticut State and Wake Forest University.

Dr. Saxton, 64, has been a director of the Company since December 2006. Dr. Saxton brings over 40 years of experience in pharmaceutical drug development to inVentiv, initially as a clinical investigator and later through more than 25 years with Pfizer Inc. until his retirement in 2001. During his time with Pfizer, Dr. Saxton worked in a variety of positions in both Europe and the USA in the R&D and International commercial divisions.

Frank C. Carlucci had served as Chairman of Nortel since April 1999. He has been a presidential advisor and served as U.S. Secretary of Defense from November 1987 to January 1989. After leaving the Department of Defense, Mr. Carlucci became Vice Chairman of The Carlyle Group, a merchant bank in Washington D.C., and has been serving as its Chairman Emeritus since January 2006. In addition to having served as President and Chief Operating Officer of Sears World Trade Center, Inc., followed by the position as Chairman and Chief Executive Officer, Mr. Carlucci has held a number of other positions in government service. His role in the Executive Branch spans four U.S. administrations of both Republican and Democratic presidents. His appointments have included Assistant to the President for National Security Affairs, Deputy Secretary of Defense, Deputy Director of Central Intelligence, Ambassador to Portugal, Undersecretary of the Department of Health, Education and Welfare, Associate, and Deputy Director of the Office of Management and Budget. He also serves on the Board of Directors of Ashland Oil, Inc.; BDM International, Inc.; Bell Atlantic Corporation; CB Commercial Real Estate Group, Inc.; Connecticut Mutual Life Insurance Company; East New York Savings Bank; General Dynamics Corporation; Kaman Corporation; Neurogen Corporation; Northern Telecom Limited; The Quaker Oats Company; SunResorts, Ltd., NV; Texas Biotechnology Corporation; Pharmacia & Upjohn, Inc.; Vinnell Corporation; Westinghouse Electric Corporation; and the Board of Trustees for the RAND Corporation. Among his awards and honors are: Herbert Roback Memorial Award, 1989; George C. Marshall Award, 1989; Honorary Doctor of Law Degree University of Scranton, 1989; Woodrow Wilson Award, 1988; James Forrestal Award, 1988; Presidential Citizens Award, 1983; National Intelligence Distinguished Service Medal, 1981; Distinguished Intelligence Medal, 1981; Defense Department Distinguished Civilian Service Award, 1977; Health, Education and Welfare Distinguished Civilian Service Award, 1975; and State Department Superior Service Award, 1971.

Dr. John L. LaMattina was appointed to be a director of Neurogen in February 2008. For approximately 30 years until his retirement in December 2007, Dr. LaMattina worked for Pfizer, Inc. most recently as Senior Vice President, Pfizer, Inc. and President, Pfizer Global Research and Development. In those roles, he oversaw the drug discovery and development efforts of over 12,000 employees in the United States, Europe, and Asia. He graduated cum laude from Boston College with a B.S. in Chemistry, received a Ph.D. from the University of New Hampshire in Organic Chemistry, and then was a National Institute of Health Post Doctorate Fellow at Princeton University. Dr. LaMattina is the author of numerous scientific publications and U.S. patents and serves on the Board of Trustees of Boston College and Worcester Polytechnic Institute and as a director of the Terri Brodeur Breast Cancer Foundation.